BHCM
LCTX icon

Brevan Howard Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Brevan Howard Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-186,794
Closed -$295K – 2352
2026
Q1 		$295K Buy
+186,794
New +$315K ﹤0.01% 1634
2025
Q3 		– Sell
-308,877
Closed -$281K – 2143
2025
Q2 		$281K Buy
+308,877
New +$183K ﹤0.01% 1575

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Brevan Howard Capital Management's LCTX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 186,794 shares — an estimated $295K sold.

Brevan Howard Capital Management first reported a position in LCTX in Q2 2025 and held it in 2 quarters. The position peaked at $295K in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 186,794 Lineage Cell Therapeutics shares in Q2 2026, an estimated $295K.
  • Brevan Howard Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's Lineage Cell Therapeutics position peaked at $295K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.